stockrowDexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
Follow DXCM
Alert me
DexCom, Inc. (DXCM) Net income
DexCom, Inc.'s net income for fiscal 2025 was $836.3M, up 45.1% from $576.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $991.0M. Over the past ten years it has ranged from −$127.1M (fiscal 2018) to $836.3M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 4 consecutive fiscal years. DexCom, Inc. ranks 9th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $836.3M | 45.14% |
| FY2024 | $576.2M | 6.41% |
| FY2023 | $541.5M | 58.70% |
| FY2022 | $341.2M | 57.31% |
| FY2021 | $216.9M | (60.54%) |
| FY2020 | $549.7M | 443.72% |
| FY2019 | $101.1M | — |
| FY2018 | −$127.1M | — |
| FY2017 | −$50.2M | — |
| FY2016 | −$65.6M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $275.1M | 10.44% |
| Jun 2026 | $249.1M | 24.86% |
| Mar 2026 | $199.5M | (25.36%) |
| Dec 2025 | $267.3M | (5.81%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| BSX Boston Scientific Corporation compare | $3.5B |
| GEHC GE HealthCare Technologies Inc. compare | $2.2B |
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| PHG Koninklijke Philips N.V. compare | $1.1B |
| EW Edwards Lifesciences Corporation compare | $1.0B |
| DXCM DexCom, Inc. | $991.0M |
| STE STERIS plc compare | $829.8M |
| ZBH Zimmer Biomet Holdings, Inc. compare | $768.8M |
| GKOS Glaukos Corporation compare | −$169.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on DXCM
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement